You are here: Home: Audio Program Guide: BCU Surgeons 2 | 2007 Audio: BCU Surgeons 2 | 2007
 
  Go to interview with Melvin J Silverstein, MD
Go to interview with David M Hyams, MD
Go to interview with Charles E Geyer Jr, MD
Go to interview with Hope S Rugo, MD
Go to highlights of The American Society of Breast Surgeons Symposium
  To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Silverstein, MD Melvin J Silverstein, MD
Professor of Surgery and Henrietta C Lee Chair in Breast Cancer Research
Chief, Breast Services, USC-Keck School of Medicine
Director, Harold E and Henrietta C Lee Breast Center
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California
  
  Click here to download the entire interview  
Track 1 Historical perspective on the local treatment of breast cancer
Track 2 Methods of partial breast irradiation (PBI)
Track 3 Delivery of intraoperative radiation therapy
Track 4 Eligibility criteria for the TARGIT study of intraoperative versus conventional external beam radiation therapy
Track 5 Oncoplastic surgery in breast cancer
Track 6 Thermal tumor ablation with cryosurgery or radiofrequency procedures

Track 7 Surgical margins and the necessity of radiation therapy in DCIS
Track 8 Breast cancer-specific mortality after invasive local recurrence among patients with DCIS
audio
Track 9 Radiation therapy for small, node-negative invasive breast tumors
audio
Track 10 Use of the Oncotype DX™ multigene assay in clinical practice
audio
Track 11 Comparison of the Oncotype DX and MammaPrint® assays
audio
Track 12 Impact of adjuvant trastuzumab for patients with HER2-positive early breast cancer
audio
Track 13 Delayed and extended adjuvant hormonal therapy
Track 14 Quality of life for patients treated with an aromatase inhibitor compared to tamoxifen
Track 15 Sentinel lymph node biopsy (SLNB) for patients with DCIS
Track 16 Use of radioisotope and blue dye in SLNB
     
Hyams, MD David M Hyams, MD
National Director of Clinical Research, Aptium Oncology
Desert Regional Medical Center
Comprehensive Cancer Center
Palm Springs, California
  
  Click here to download the entire interview  
Track 1 Case discussion: A 61-year-old woman with a 1-cm, Grade II, strongly ER-positive and PR-positive, HER2-negative breast tumor
Track 2 Patient’s attitude toward breast-conserving surgery and radiation therapy
Track 3 Oncoplastic approach to breast-conserving surgery
Track 4 Sentinel lymph node biopsy
Track 5 TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx)
Track 6 Patient reactions to clinical trial participation

Track 7 Adjuvant chemotherapy for node-negative, hormone receptor-positive tumors
Track 8 Defining intermediate recurrence score in TAILORx
Track 9 Chemotherapy options in TAILORx
Track 10 Side effects and tolerability of adjuvant hormonal therapies
Track 11 Extended adjuvant hormonal therapy with aromatase inhibitors
Track 12 Long-term risk of recurrence for patients with hormone receptor-positive early breast cancer

Track 13 NSABP-B-39: Conventional versus partial breast irradiation
Track 14 Potential advantages of PBI techniques
Track 15 Radiation recall with external beam PBI
Track 16 Discussing randomized clinical trial options with patients
     
Geyer, MD Charles E Geyer Jr, MD
Director of Medical Affairs
National Surgical Adjuvant Breast and Bowel Project
Director of Breast Medical Oncology
Allegheny General Hospital
Pittsburgh, Pennsylvania
  
  Click here to download the entire interview  
Track 1 Case discussion: A 49-year-old woman with a 0.8-cm, node-negative breast tumor
Track 2 Impact of hormonal therapy for patients with high Oncotype DX recurrence scores
Track 3 MammaPrint multigene assay
Track 4 Selection of initial adjuvant hormonal therapy for postmenopausal patients
Track 5 Long natural history of hormone receptor-positive breast cancer: Implications for treatment
Track 6 NSABP-B-33: Exemestane versus no treatment after five years of adjuvant tamoxifen

Track 7 Arthralgias associated with aromatase inhibitors
Track 8 Delayed, extended adjuvant hormonal therapy
Track 9 NSABP-B-42: Letrozole after either five years of an adjuvant aromatase inhibitor or tamoxifen followed by
an aromatase inhibitor
Track 10 Long-term safety of aromatase inhibitors
Track 11 Hormonal therapy for perimenopausal patients at risk for thromboembolic events
Track 12 Estradiol suppression with aromatase inhibitors in obese women
Track 13 Adjuvant trastuzumab for HER2-positive early breast cancer

Track 14 Rate of congestive heart failure associated with adjuvant chemotherapy/trastuzumab
Track 15 Treatment of small, node-negative, HER2- positive tumors
Track 16 Adjuvant trastuzumab monotherapy
audio
     
Rugo, MD Hope S Rugo, MD
Clinical Professor of Medicine
Carol Franc Buck Breast Care Center
Co-director, Breast Oncology Clinical Trials Program
University of California, San Francisco
Comprehensive Cancer Center
San Francisco, California
  
  Click here to download the entire interview  
Track 1 Case discussion: A postmenopausal woman with node-positive breast cancer who received extended adjuvant hormonal therapy
Track 2 Risk of recurrence for patients with hormone receptor-positive disease after five years of treatment
Track 3 Individualizing treatment options for patients who have completed five years of adjuvant hormonal therapy
Track 4 Aging, use of aromatase inhibitors and joint pain
Track 5 Clinical disease management for premenopausal patients who have completed five years of adjuvant hormonal therapy
Track 6 Case discussion: A 60-year-old woman with hormone receptor-negative, HER2-positive breast cancer who received adjuvant chemotherapy and trastuzumab
audio
Track 7 BCIRG 006 adjuvant trastuzumab trial: Docetaxel/carboplatin/trastuzumab (TCH)
audio
Track 8 Risk of congestive heart failure with adjuvant trastuzumab
audio
Track 9 Acceptance of adjuvant trastuzumab therapy by patients with HER2-positive early breast cancer
audio
Track 10 Use of adjuvant trastuzumab without chemotherapy
audio
Track 11 Quality of life and side effects with trastuzumab
audio
Track 12 Importance of obtaining adequate tissue for assessment of HER2 and ER status
audio
Track 13 Selection of patients for neoadjuvant therapy
audio
Track 14 Treatment approach to residual disease after neoadjuvant chemotherapy
audio
     
  The American Society of Breast Surgeons Symposium
A CME Symposium Held in Conjunction with The American Society of
Breast Surgeons Eighth Annual Meeting

  
  Click here to download the entire discussion  
Track 1 Case discussion: A 49-year-old perimenopausal woman with a 1-cm, Grade II, strongly ER-positive and PR-positive, HER2-negative, node-negative infiltrating ductal carcinoma (IDC)
Track 2 Use of the Oncotype DX assay to assist in treatment decision-making
Track 3 Adjuvant chemotherapy for small, node-negative tumors
Track 4 Endocrine therapy for perimenopausal patients
Track 5 Tolerability and side effects of tamoxifen and aromatase inhibitors
audio
Track 6 Case discussion: A 61-year-old woman with a 0.8-cm, strongly hormone receptor-positive, HER2-negative, node-negative IDC
audio
Track 7 Counseling patients about participation in TAILORx
audio
Track 8 NSABP-B-39: Conventional versus partial breast irradiation
audio
Track 9 Radiation recall reaction to PBI
audio
Track 10 TARGIT study of intraoperative radiation therapy
audio
Track 11 Case discussion: A 29-year-old woman with a locally advanced, hormone receptor-positive, HER2-positive IDC
audio
Track 12 Adjuvant ovarian suppression and anastrozole in a premenopausal patient intolerant of tamoxifen
audio
Track 13 Treatment of HER2-positive early breast cancer
audio